Autoimmune Bullous Disease Quality of Life (ABQoL) questionnaire: Validation of the translated Persian version in pemphigus vulgaris
Background: Autoimmune bullous diseases are a group of rare, chronic, blistering diseases, with pemphigus vulgaris (PV) being the most common type in Iran. Skin and mucosal involvement and therapy may have a dismal impact on the quality of life of affected patients. Objective: We aimed to assess the...
Saved in:
Main Authors: | Amir Teimourpour, PhD (Author), Kowsar Hedayat, MD (Author), Fereshteh Salarvand, MD (Author), Narges Ghandi, MD (Author), Maryam Ghiasi, MD (Author), Hamidreza Mahmoudi, MD (Author), Kamran Balighi, MD (Author), Roja Toosi, MD, MPH (Author), Farnam Mohebi, MD, MPH (Author), Ali Nili, MD (Author), Maryam Daneshpazhooh, MD (Author), Dedee F. Murrell, MA, BMBCh, MD, FACD (Author), Cheyda Chams-Davatchi, MD (Author) |
---|---|
Format: | Book |
Published: |
Wolters Kluwer,
2020-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Family impact of pemphigus disease in an Iranian population using the Family Dermatology Life Quality Index
by: S. Zahra Ghodsi, MD, et al.
Published: (2020) -
Short-term clinical and serological follow-up with conventional and conformational anti-desmoglein antibodies in treatment-naïve and previously treated patients with pemphigus vulgaris after receiving rituximab
by: Hoorieh Alaeen, MD, et al.
Published: (2019) -
Pregnancy outcomes in women with pemphigus exposed to rituximab before or during pregnancy
by: Azin Dehghanimahmoudabadi, MD, et al.
Published: (2022) -
Burden of pemphigus vulgaris with a particular focus on women: A review
by: Nika Kianfar, MD-MPH, et al.
Published: (2022) -
Assessing quality of life in patients with autoimmune bullous diseases using the Persian version of Treatment of Autoimmune Bullous Disease Quality of Life questionnaire finds similar effects in women as men
by: Atefeh Behkar, MD, MPH, et al.
Published: (2022)